BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Catalyst Brief//FDA catalyst calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Catalyst Brief — FDA catalyst calendar
REFRESH-INTERVAL;VALUE=DURATION:PT6H
X-PUBLISHED-TTL:PT6H
BEGIN:VEVENT
UID:event-121@catalystbrief.girapphe.com
DTSTAMP:20261117T181555Z
LAST-MODIFIED:20261117T181555Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Readout: Epizyme\, Inc. — Tazemetostat [Feb 2027]
DESCRIPTION:Phase 3 primary completion: A Study to Assess the Efficacy\, Sa
 fety\, Pharmacodynamics\, and Pharmacokinetics of Tazemetostat in Combinat
 ion With Lenalidomide Plus Rituximab Versus Placebo in Combination With Le
 nalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With 
 Relapsed/Refractory Follicular Lymphoma..\nSource: https://clinicaltrials.
 gov/study/NCT04224493\nhttps://catalystbrief.girapphe.com/e/121?lang=en\nN
 ot investment advice. Dates may change.
URL:https://catalystbrief.girapphe.com/e/121?lang=en
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
